Veronica Sanchez Bulis - 10 Feb 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
VP, Corporate Controller
Signature
/s/ Mark Meltz, Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
10 Feb 2026
Net transactions value
-$5,872
Form type
4
Filing time
11 Feb 2026, 21:00:26 UTC
Previous filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bulis Veronica Sanchez VP, Corporate Controller C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO /s/ Mark Meltz, Attorney-in-Fact 11 Feb 2026 0002095702

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +8,750 +123% $0.000000 15,891 10 Feb 2026 Direct F1
transaction LYEL Common Stock Sale $5,872 -254 -1.6% $23.12 15,637 10 Feb 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan. 12.5% of the total number of restricted stock units will vest on August 9, 2026, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
F2 Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.